Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Robotic Assisted Major Lung Resection in Elderly Patients

NCT06496386 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2024-09-30
Last updated
2024-11-27

Condition(s) studied

Lung Cancer

Study summary

The study is a retrospective observational study. The study is designed to be multicentric and it will analyze medical records from selected patients that underwent major lung resection using DaVinci surgical platform performed in the participating centers.

There are no risks for the patients, as this is a retrospective data collection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>18 years at the moment of surgery * Suspected or confirmed diagnosis of lung cancer * The patient can be candidate in terms of cardiac, kidney, liver and respiratory function the primary pathology is under control or controllable * Absence of extrapulmonary metastases that are not controlled or controllable * All procedures included use of DaVinci robot system Exclusion Criteria: * Age \< 18 years at the moment of surgery * Patients who cannot undergo surgery, as they do not meet the conditions outlined above

Primary outcome measure(s)

  • The perioperative complications — from the surgery at 30-90 days after
    the investigators will measure the perioperative complications of robotic lung resection in patients with 80 or more than 80 years (very elderly patients) compared to those with less than 80 years. Complications will be categorized according to the Clavien-Dindo scale.
  • spirometry tests — from hospitalizzation to the discharge date at maximum one week
    the investigators will measure the pre-operative respiratory function (Forced expiratory volume (FEV) , forced vital capacity (FVC)), in the two groups .
  • Postoperative hospital stay — from hospitalizzation to the discharge date at maximum one week
    the investigators will measure the post-operative hospital stay in days in the two groups.

Trial sites (2)

FacilityCityRegionStatus
Istituto Clinico Humanitas Rozzano Milan Recruiting
Scientific Institute Ospedale San Raffaele Milan Italy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06496386 on ClinicalTrials.gov ↗ ← All trials in Italy